Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
To determine the MTD or OBD of MEDI-551 in participants with relapsed or refractory advanced B-cell malignancies.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed CLL, DLBCL, FL, or MM;
Karnofsky Performance Status \>= 70;
Life expectancy of \>= 12 weeks;
Prior radiation therapy provided exposure does not exceed an area of 25% of marrow space
Adequate hematological function
Adequate organ function
You may not be if
Any available standard line of therapy known to be life-prolonging or life-saving;
No concurrent therapy or therapy within six weeks of first dose of MEDI-551 for treatment of cancer
Previous therapy directed against CD19
Vaccination (other than experimental cancer vaccine therapy) within 28 days prior to receiving the first dose of MEDI-551;
History of other invasive malignancy within 5 years except for cervical carcinoma in situ (CIS), non-melanomatous carcinoma of the skin or ductal carcinoma in situ (DCIS) of the breast that have been surgically cured;
Active infection requiring treatment
Autologous stem cell transplantation within 4 months prior to study entry;
Allogeneic stem cell transplantation or any other organ transplant;
Use of immunosuppressive medication other than steroids within 28 days before the first dose of MEDI-551;
Use of immunosuppressive medication other than steroids within 28 days before the first dose of MEDI-551 (inhaled and topical corticosteroids are permitted);
Documented current central nervous system involvement by leukemia or lymphoma;
